)
Watch and Learn More
About DUPIXENT
CRSwNP MECHANISM OF ACTION VIDEO
Take a deeper dive into the mechanism of action of DUPIXENT
DUPIXENT is indicated as an add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps, or CRS with NP.
CRS with NP is predominantly characterized by type 2 inflammation of the nose and paranasal sinuses and is frequently associated with comorbidities.
IL-4 and IL-13 are type 2 cytokines that play key roles in CRS with NP, including Th2 cell differentiation, eosinophil trafficking, and B-cell switching to IgE release.
DUPIXENT is the first and only dual inhibitor of IL-4 and IL-13 signaling addressing type 2 inflammation that contributes to CRS with NP. The mechanism of dupilumab action has not been definitively established.
In the inflammatory process, IL-4 binds to the IL-4 receptor alpha subunit at the type 1 receptor, and IL-13 binds to the IL-13 receptor alpha 1 subunit at the type 2 receptor. IL-4 can also bind to the IL-4 receptor alpha subunit at the type 2 receptor, and each interaction transmits its own signal downstream. DUPIXENT binds to IL-4 receptor alpha subunit, blocking IL-4 and IL-13 intracellular signaling. This results in reduced expression of pro-inflammatory cytokines, ultimately leading to decreased total and specific IgE. In addition, there is an impact on eosinophil activation and trafficking, along with other mechanisms that decrease type 2 inflammation. DUPIXENT is the first and only dual inhibitor of IL-4 and IL-13 signaling, two cytokines that contribute to underlying type 2 inflammation in CRS with NP.
Important Safety
Information and Indication
CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.
WARNINGS AND PRECAUTIONS
Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.
Conjunctivitis and Keratitis: Conjunctivitis occurred more frequently in subjects with chronic rhinosinusitis with nasal polyps who received DUPIXENT compared to those who received placebo. There were no cases of keratitis reported in the CRS with NP development program. Conjunctivitis and keratitis have been reported with DUPIXENT in post-marketing settings, with some patients reporting visual disturbances (for example, blurred vision). Advise patients or their caregivers to report new onset or worsening eye symptoms to their healthcare provider. Consider ophthalmological examination for patients who develop conjunctivitis that does not resolve following standard treatment or signs and symptoms suggestive of keratitis, as appropriate.
Eosinophilic Conditions: Patients being treated for asthma may present with serious systemic eosinophilia sometimes presenting with clinical features of eosinophilic pneumonia or vasculitis consistent with eosinophilic granulomatosis with polyangiitis (EGPA), conditions which are often treated with systemic corticosteroid therapy. These events may be associated with the reduction of oral corticosteroid therapy. Healthcare providers should be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients with eosinophilia. Cases of eosinophilic pneumonia were reported in adult patients who participated in the asthma development program and cases of vasculitis consistent with EGPA have been reported with DUPIXENT in adult patients who participated in the asthma development program as well as in adult patients with co-morbid asthma in the CRS with NP development program. A causal association between DUPIXENT and these conditions has not been established.
Risk Associated with Abrupt Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation of DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a healthcare provider. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.
Patients with Co-morbid Asthma: Advise patients with co-morbid asthma not to adjust or stop their asthma treatments without consultation with their physicians.
Arthralgia: Arthralgia has been reported with use of DUPIXENT with some patients reporting gait disturbances or decreased mobility associated with joint symptoms; some cases resulted in hospitalization. Advise patients to report new onset or worsening joint symptoms. If the symptoms persist or worsen, consider rheumatological evaluation and/or discontinuation of DUPIXENT.
Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves.
Vaccinations: Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating DUPIXENT. Avoid use of live vaccines during treatment with DUPIXENT.
ADVERSE REACTIONS: The most common adverse reactions (incidence ≥ 1%) in patients with CRS with NP are injection site reactions, eosinophilia, insomnia, toothache, gastritis, arthralgia, and conjunctivitis.
USE IN SPECIFIC POPULATIONS
- Pregnancy: A pregnancy exposure registry monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. To enroll or obtain information call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
- Lactation: There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.
Please see accompanying full Prescribing Information.
Indication
DUPIXENT is indicated as an add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRS with NP).
Mark Your Calendars for These Events
The American Academy
of Otolaryngic Allergy
(AAOA)
November 2025
American Rhinologic
Society (ARS)
May 2025
American College of
Allergy, Asthma &
Immunology (ACAAI)
November 2025
CRSwNP, chronic rhinosinusitis with nasal polyps.
Download and Discover More About DUPIXENT
Join Us at Virtual Educational Events for DUPIXENT in 2022
Explore Dupixent Like Never Before
Tour the DUPIXENT virtual booth to learn more information about this biologic, including appropriate patient types, its MOA, efficacy and safety data, and how to help your appropriate patients start and stay on track with DUPIXENT.
VISIT BOOTHMark Your Calendars for These Events
American College of
Allergy, Asthma &
Immunology (ACAAI)
November 2023
Have More Questions? Get Answers.
Visit the FAQ page to learn more about DUPIXENT and how it may be able to help patients.
Support can make all the difference for patients. DUPIXENT MyWay® is a patient support
program that can get them started on DUPIXENT with coverage support, financial assistance for eligible patients, one‑on‑one nursing support, and more.
program that can get them started on DUPIXENT with coverage support, financial assistance for eligible patients, one‑on‑one nursing support, and more.
Contact a Field
Representative
Connect with a DUPIXENT Field
Representative to get answers to your
product‑related
questions and request
samples.